An overview on GlyT-1 inhibitors under evaluation for the treatment of schizophrenia

Drugs of the Future

Volumn 38, Issue 8, 2013, Pages 555-568

  Harsing Jr , Laszlo G ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Antipsychotic agents; Glycine transporters; Glycyldocecylamide; Schizophrenia

Indexed keywords

2 CHLORO N [ALPHA (2 PIPERIDINYL)BENZYL] 3 TRIFLUOROMETHYLBENZAMIDE; AMG 747; ANANDAMIDE; ARACHIDONIC ACID; ASP 2535; ATYPICAL ANTIPSYCHOTIC AGENT; BENZAMIDE DERIVATIVE; BITOPERTIN; GLYCINE; GLYCINE TRANSPORTER 1; GLYCINE TRANSPORTER 1 INHIBITOR; GLYCYLDODECYLAMIDE; GSK 1018921; GT 1109727; INDAN DERIVATIVE; LY 2365109; N [3 (4 FLUOROPHENYL) 3 (4 PHENYLPHENOXY)PROPYL]SARCOSINE; NEUROLEPTIC AGENT; OLANZAPINE; ORG 24461; ORG 25935; PF 3463275; PHENCYCLIDINE; RO 4543338; SARCOSINE; SARCOSINE DERIVATIVE; SSR 103800; TETRALINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; [4 PHENYL 1 (PROPYLSULFONYL)PIPERDIN 4 YL]METHYL BENZAMIDE;

ADD ON THERAPY; AGORAPHOBIA; AKATHISIA; ALCOHOLISM; ALZHEIMER DISEASE; ANXIETY DISORDER; ATAXIA; BEHAVIOR THERAPY; BINDING SITE; BRAIN SYNAPTOSOME; BRIEF PSYCHIATRIC RATING SCALE; CENTRAL NERVOUS SYSTEM; CHEMICAL STRUCTURE; CHRONIC DISEASE; CHRONIC PAIN; COCAINE DEPENDENCE; COGNITIVE DEFECT; COGNITIVE THERAPY; COMORBIDITY; CONVULSION; DEGENERATIVE DISEASE; DEPRESSION; DIZZINESS; DOPAMINERGIC TRANSMISSION; DOSE RESPONSE; DRUG ABUSE; DRUG DEPENDENCE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FOREBRAIN; HEADACHE; HUMAN; MEMORY DISORDER; MENTAL DISEASE; NEUROBIOLOGY; NEUROLOGIC DISEASE; NEUROPATHIC PAIN; NEUROPHARMACOLOGY; NEUROTRANSMISSION; NONHUMAN; PAIN; PANIC; PATHOGENESIS; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSITIVE AND NEGATIVE AFFECT SCHEDULE; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PREPULSE INHIBITION; PSYCHOPHARMACOLOGY; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATION DEPRESSION; REVIEW; SCHIZOPHRENIA; SINGLE DRUG DOSE; SOMNOLENCE; STARTLE REFLEX; SYMPTOM; TOBACCO DEPENDENCE; TOXICITY TESTING; TREATMENT RESPONSE; WORKING MEMORY;

EID: 84930541850     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2013.038.08.1965101     Document Type: Review

References (118)

1. Toth, E., Weiss, B., Banay-Schwartz, M., Lajtha, A. Effect of glycine derivatives on behavioral changes induced by 3-mercaptoproprionic acid or phencyclidine in mice. Res Comm Psychol Psychiatr Behav 1986, 11: 1.
2. Javitt, D.C., Frusciante, M. Glycyldodecylamide, a phencyclidine behavioural antagonists, blocks cortical glycine uptake: Implication for schizophrenia and substance abuse. Psychopharmacology 1997, 129(1): 96-8.
3. Tamminga, C.A. Schizophrenia and glutamatergic transmission. Crit Rev Neurobiol 1998, 12(1-2): 21-36.
4. Javitt, D.C., Zylberman, I., Zukin, S.R., Heresco-Levy, U., Lindenmayer, J.P. Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry 1994, 151(8): 1234-6.
5. Zafra, F., Alcantara, R., Gomeza, J., Aragon, C., Gimenez, C. Arachidonic acid inhibits glycine transport in cultured glial cells. Biochem J 1990, 271(1): 237-42.
6. Pearlman, R.J., Aubrey, K.R., Vandenberg, R.J. Arachidonic acid and anandamide have opposite modulatory actions at the glycine transporter, GLYT1a. J Neurochem 2003, 84(3): 592-601.
7. Carland, J.E., Mansfield, R.E., Ryan, R.M., Vandenberg, R.J. Oleyl-L-carnitine inhibits glycine transport by GlyT2. Br J Pharmacol 2013, 168(4): 891-902.
8. Harsing, L.G. Jr., Zsilla, G., Matyus, P., Nagy, K.M., Marko, B., Gyarmati, Z., Timar, J. Interactions between glycine transporter type 1 (GlyT-1) and some inhibitor molecules. Acta Physiol Hung 2012, 99(1): 1-17.
9. Lowe, J.A. III, Drozda, S., Qian, W. et al. A Novel, non-substrate-based series of glycine type 1 transporter inhibitors derived from high-throughput screening. Bioorg Med Chem Lett 2007, 17(6): 1675-8.
10. Thomsen, C. Glycine transporter inhibitors as Novel antipsychotics. Drug Discovery Today: Therapeutic Strategies 2006, 3(4): 539-45.
11. Harsing, L.G. Jr., Juranyi, Z., Gacsalyi, I., Tapolcsanyi, P., Czompa, A., Matyus, P. Glycine transporter type-1 and its inhibitors. Curr Med Chem 2006, 13(9): 1017-44.
12. Herdon, H.J., Godfrey, F.M., Brown, A.M., Coulton, S., Evans, J.R., Cairns, W.J. Pharmacological assessment of the role of glycine transporter GlyT-1 in mediating high affinity glycine uptake by rat cerebral cortex and cerebellum synaptosomes. Neuropharmacology 2001, 41(1): 88-96.
13. Brown, A., Carlyle, I., Clark, J. et al. Discovery and SAR of Org 24598 - A selective glycine uptake inhibitor. Bioorg Med Chem Lett 2001, 11(15): 2007-9.
14. Harsing, L.G. Jr., Gacsalyi, I., Schmidt, E. et al. The glycine transporter 1 inhibitor NFPS and Org-24461: A pharmacological study. Pharmacol Biochem Behav 2003, 74(4): 811-25.
15. Kinney, G.C., Sur, C., Burno, N.J. et al. The glycine transporter type 1 inhibitor N-[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl]sarcosine potentiates NMDA receptor-mediated responses in vivo and produces an antipsychotic profile in rodent behaviour. J Neurosci 2003, 23(20): 7586-91.
16. Perry, K.W., Falcone, J.F., Fell, M.J. et al. Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs. cortical brain areas. Neuropharmacology 2008, 55(5): 743-54.
17. Kopec, K., Flood, D.G., Gasior, M. et al. Glycine transporter (GlyT1) inhibitors with reduced residence time increase prepulse inhibition without inducing hyperlocomotion in DBA/2 mice. Biochem Pharmacol 2010, 80(9): 1407-17.
18. Depoortere, R., Dargazanli, G., Estenne-Bouhtou, G. et al. Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic. Neuropsychopharmacology 2005, 30(11): 1963-85.
19. Boulay, D., Pichat, Ph., Dargazanli, G. et al. Characterization of SSR103800, a selective inhibitor of the glycine transporter-1 in models predictive of therapeutic activity in schizophrenia. Pharmacol Biochem Behav 2008, 91(1): 47-58.
20. Pinard, E., Alberati, D., Bender, M. et al. Discovery of benzoylisoindolines as a Novel class of potent, selective and orally active GlyT1 inhibitors. Bioorg Med Chem Lett 2010, 20(23): 6960-5.
21. Alberati, D., Moreau, J.-L., Lengyel, J. et al. Glycine reuptake inhibitor RG1678: A pharmacological characterization of an investigational agent for the treatment of schizophrenia. Neuropharmacology 2012, 62(2): 1152-61.
22. Lindsley, C.W., Zhao, Z., Leister, W.H. et al. Design, synthesis, and in vivo efficacy of Novel glycine transporter-1 (GlyT1) inhibitors derived from a series of [4-phenyl-1-(propylsulfonyl)piperidin-4-yl]methyl benzamides. Chem Med Chem 2006, 1(8): 807-11.
23. Harada, K., Nakato, K., Yarimizu, J. et al. A Novel glycine transporter-1 (GlyT1) inhibitor, ASP2535 (4-[3-isopropyl-5-(6-phenyl-3-pyridyl)-4H-1,2,4- triazol-4-yl]-2,1,3-benzoxadiazole), improves cognition in animal models of cognitive impairment in schizophrenia and Alzheimer's disease. Eur J Pharmacol 2012, 685(1-3): 59-69.
24. Slassi, A., Egle, I. Recent progress in the use of glycine transporter-1 inhibitors for the treatment of central and peripheral nervous system disease. Expert Opin Ther Patents 2004, 14(2): 201-14.
25. Kinney, G.G., Sur, C. Glycine site modulators and glycine transporter-1 inhibitors as Novel therapeutic targets for the treatment of schizophrenia. Curr Neuropharmacol 2005, 3(1): 35-43.
26. Lindsley, C.W., Shipe, W.D., Wolkenberg, S.E., Theberge, C.R., Williams, D.L. Jr., Sur, C., Kinney, G.G. Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia. Curr Topics Med Chem 2006, 6(8): 771-85.
27. Hashimoto, K. Glycine transporter inhibitors as therapeutic agents for schizophrenia. Recent Pat CNS Drug Discov 2006, 1(1): 43-53.
28. Hashimoto, K. Glycine transport inhibitors for the treatment of schizophrenia. Open Med Chem J 2010, 4: 10-9.
29. Gerther, U., Andersen, P.H., Larsson, O.M., Schousboe, A. Neurotransmitter transporters: Molecular function of important drug treatments. Trends Pharm Sci 2006, 27(7): 375-83.
30. Zafra, F., Aragon, C. Oliveras, L., Danbolt, N.C., Gimenez, C., Storm-Mathisen, J. Glycine transporters are differently expressed among CNS cells. J Neurosci 1995, 15(5, Pt. 2): 3952-69.
31. Harsing, L.G. Jr., Matyus, P. Mechanisms of glycine release, which build up synaptic and extrasynaptic glycine levels: The role of synaptic and nonsynaptic glycine transporters. Brain Res Bull 2013, 93: 110-9.
32. Raiteri, L., Raiteri, M. Functional "glial" GlyT1 glycine transporters expressed in neurons. J Neurochem 2010, 114(3): 647-53.
33. Cubelos, B., Gimenez, C., Zafra, F. Localization of the GLYT1 glycine transporter at glutamatergic synapses in the rat brain. Cereb Cortex 2005, 15(4): 448-59.
34. Gomeaza, J., Hülsmann, S., Ohno, K., Eulenburg, V., Szoke, K., Richter, D., Betz, H. Inactivation of the glycine transporter 1 gene discloses vital role of glial glycine uptake in glycinergic inhibition. Neuron 2003, 40(4): 785-96.
35. Kalbaugh, T.L., Zhang, J., Diamond, J.S. Coagonist release modulates NMDA receptor subtype contributions at synaptic inputs to retinal ganglion cells. J Neurosci 2009, 29(5): 1469-79.
36. Harsing, L.G. Jr., Albert, M., Matyus, P., Szenasi, G. Inhibition of hypoxiainduced [3H]glycine release from chicken retina by the glycine transporter type-1 (GlyT-1) inhibitors NFPS and Org-24461. Exp Eye Res 2012, 94(1): 6-12.
37. Papp, A., Juranyi, Z., Nagymajtenyi, L., Matyus, P., Harsing, L.G. Jr. The synaptic and nonsynaptic glycine transporter type-1 inhibitors Org-24461 and NFPS alter single neuron firing rate in the rat dorsal raphe nucleus. Further evidence for a glutamatergic-serotonergic interaction and its role in antipsychotic action. Neurochem Int 2008, 52(1-2): 130-4.
38. Gray, J.A., Nicoll, R.A. Thinking outside the synapse: Glycine at extrasynaptic NMDA receptors. Cell 2012, 150(3): 455-6.
39. Kalinichev, M., Starr, K.R., Teague, S., Bradford, A.M., Porter, R.A., Herdon, H.J. Glycine transporter 1 (GlyT1) inhibitors exhibit anticonvulsant properties in the rat maximal electroshock threshold. Brain Res 2010, 1331: 105-13.
40. Vizi, E.S., Kisfali, M., Lorincz, T. Role of nonsynaptic GluN2B-containing NMDA receptors in exocytosis: Evidence that fluoxetine selectively inhibits these receptors and may have neuroprotective effects. Brain Res Bull 2013, 93: 32-8.
41. Tovar, K.R., Westbrook, G.L. The incorporation of NMDA receptors with a distinct subunit composition at nascent hippocampal synapses in vitro. J Neurosci 1999, 19(10): 4180-8.
42. Imamura, Y., Ma, Chun-Lei, Pabba, M., Bergeron, R. Sustained saturating level of glycine induces changes in NR2B-containing-NMDA receptor localization in the CA1 region of the hippocampus. J Neurochem 2008, 105(6): 2454-65.
43. Papouin, T., Ladepeche, L., Ruel, J. et al. Synaptic and extrasynaptic NMDA receptors are gated by different endogenous coagonists. Cell 2012, 150(3): 633-46.
44. Nagy, K.M., Marko, B., Zsilla, G. et al. Alterations in brain extracellular dopamine and glycine levels following combined administration of the glycine transporter type-1 inhibitor Org-24461 and risperidone. Neurochem Res 2010, 35(12): 2096-106.
45. Tsai, G., Yang, P., Chung, L.-C., Lange, N., Coyle, J.T. D-Serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 1998, 44(11): 1081-9.
46. Mezler, M., Hornberger, W., Mueller, R. et al. Inhibitors of GlyT1 affect glycine transport via discrete binding sites. Mol Pharmacol 2008, 74(6): 1705-15.
47. Toth, E., Lajtha, A. Anatagonism of phencyclidine-induced hyperactivity by glycine in mice. Neurochem Res 1986, 11(3): 393-400.
48. Alberati, D., Moreau, J.-L., Mory, R., Pinard, E., Wettstein, J.G. Pharmacological evaluation of a Novel assay for detecting glycine transporter 1 inhibitors and their antipsychotic potential. Pharm Biochem Behav 2010, 97(2): 185-91.
49. Andersen, J.D., Pouzet, B. Spatial memory deficits induced by perinatal treatment of rats with PCP and reversal effect of D-serine. Neuropsychopharmacology 2004, 29(6): 1080-90.
50. Hashimoto, K., Fujita, Y., Ishima, T., Chaki, S., Iyo, M. Phencyclidineinduced cognitive deficits in mice are improved by subsequent, subchronic administration of the glycine trasporter-1 inhibitor NFPS and D-serine. Eur Neuropsychopharmacol 2007, 18(6): 414-21.
51. Zlomuzica, A., De Souza Silva, M.A., Huston, J.P., Dere, E. NMDA receptor modulation by D-cycloserine promotes episodic-like memory in mice. Psychopharmacology 2007, 193(4): 503-9.
52. Manahan-Vaughan, D., Wildförster, V., Thomsen, C. Rescue of hippocampal LTP and learning deficits in a rat model of psychosis by inhibition of glycine transporter-1 (GlyT1). Eur J Neurosci 2008, 28(7): 1342-50.
53. Black, M.D., Varty, G.B., Arad, M. et al. Procognitive and antipsychotic efficacy of glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia: Latent inhibition studies in the rat. Psychopharmacology 2009, 202(1-3): 385-96.
54. Javitt, D.C., Sershen, H., Hashim, A., Lajtha, A. Inhibition of striatal dopamine release by glycine and glycyldodecylamide. Brain Res Bull 2000, 52(3): 213-6.
55. Heresco-Levy, U., Silipo, G., Javitt, D.C. Glycinergic augmentation of NMDA receptor-mediated neurotransmission in the treatment of schizophrenia. Psychopharmacol Bull 1996, 32(4): 731-40.
56. Hersesco-Levy, U., Javitt, D.C., Ermilov, M., Mordel, C., Horowitz, A., Kelly, D. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment resistant schizophrenia. Br J Psychiatry 1996, 169(5): 610-7.
57. Hersesco-Levy, U., Javitt, D.C., Ermilov, M., Mordel, C., Silipo, G., Lichtenstein, M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry 1999, 56(1): 29-36.
58. Evins, A.E., Fitzgerald, S.M., Wine, L., Rosselli, R., Goff, D.C. Placebo controlled trial of glycine added to clozapine in schizophrenia. Am J Psychiatry 2000, 157(5): 826-8.
59. Goff, D.C., Tsai, G., Levitt, J. et al. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry 1999, 56(1): 21-7.
60. Evins, A.E., Amico, E., Posever, T.A., Toker, R., Goff, D.C. D-Cycloserine added to risperidone in patients with primary negative symptoms of schizo phrenia. Schizophrenia Res 2002, 56(1-2): 19-3.
61. Goff, D.C., Henderson, D.C., Evins, E., Amico, E. A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia. Biol Psychiatry 1999, 45(4): 512-4.
62. Heresco-Levy, U., Ermilov, M., Lichtenbertg, P., Bar, G., Javitt, D.C. Highdose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biol Psychiatry 2004, 55(2): 165-71.
63. Heresco-Levy, U., Javitt, D.C., Ebstein, R. et al. D-Serine efficacy as addon pharmacotherapy to risperidone and olanzapine for the treatmentrefractory schizophrenia. Biol Psychiatry 2005, 57(6): 577-85.
64. Buchanan, R.W., Javitt, D.C., Marder, S.R. et al. The Cognitive and Negative Symptoms in Schizophrenia trial (CONSIST): The efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry 2007, 164(10): 1593-602.
65. Weiser, M., Heresco-Levy, U., Davidson, M. et al. A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia. J Clin Psychiatry 2012, 73(6): e728-34.
66. Tsai, G., Lane, H.-Y., Yang, P., Chong, M.-Y., Lange, N. Glycine transporter I inhibitor N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 2004, 55(5): 452-6.
67. Lane, H.-Y., Chang, Y.-C., Liu, Y.-C., Chiu, C.-C., Tsai, G.E. Sarcosine or Dserine add-on treatment for acute exacerbation of schizophrenia. Arch Gen Psychiatry 2005, 62(11): 1196-204.
68. Lane, H.Y., Liu, Y.C., Huang, CL., Chang, Y.C., Liau, C.H., Pemg, C.H., Tsai, G.E. Sarcosine (N-methylglycine) treatment for acute schizophrenia: A randomized, double-blind study. Biol Psychiatry 2008, 63(1): 9-12.
69. Lane, H.-Y., Huang, C.-L., Wu, P.-L. et al. Glycine transporter I inhibitor, Nmethylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. Biol Psychiatry 2006, 60(6): 645-9.
70. Tsai, G.E., Yang, P., Chang, Y.-C., Chong, M.-Y. D-Alanine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 2006, 59(3): 230-4.
71. Williams, J.B., Mallorga, P.J., Conn, P.J., Pettibone, D.J., Sur, C. Effects of typical and atypical antipsychotics on human glycine transporters. Schizophrenia Res 2004, 71(1): 103-12.
72. Sanabria-Bohorquez, S.M., Joshi, A.D., Holahan, M. et al. Quantification of the glycine transporter 1 in rhesus monkey brain using [18F]MK-6577 and a model-based input function. NeuroImage 2012, 59(3): 2589-99.
73. Wong, D.F., Ostrowitzki, S., Zhou, Y. et al. Characterization of [11C]RO5013853, a Novel PET tracer for the glycine transporter type 1 (GlyT1) in humans. NeuroImage 2013, 75C: 282-90.
74. A study of bitopertin (RO4917838) in healthy male volunteers (NCT01636492). ClinicalTrials.gov Web site, May 28, 2013.
75. Umbricht, D., Kisook, Y., Youssef, E. et al. Glycine transporter type1 (GLYT1) inhibitor RG1678: Positive results of the proof-of-concept study for the treatment of negative symptoms in schizophrenia. 49th Annu Meet Am Coll Neuropsychopharmacol (ACNP) 2010, Abst 049.
76. Umbricht, D., Martin-Facklam, M., Pizzagalli, F. Glycine transporter type1 (GlyT1) inhibitor RG1678: Results of the proof-of-concept study for the treatment of negative symptoms in schizophrenia. 28th CINP World Congr Neuropsychopharmacol 2012, S28.
77. D'Souza, D.C., Singh, N., Elander, J. et al. Glycine transporter inhibitor attenuates the psychotomimetic effects of ketamine in healthy males: Preliminary evidence. Neuropsychopharmacology 2012, 37(4): 1036-46.
78. Dogterom, P., Thomson, F., Hargreaves, R. et al. Characterization of the relationship between target occupancy/modulation and preclinical/clinical responses for the glycine transporter1 (GlyT1) inhibitor Org25935. 49th Annu Meet Am Coll Neuropsychopharmacol (ACNP) 2011, p. 361.
79. Szegedi, A., Jansen, W., Karson, C., Schipper, J., Schoemaker, J. Adjunctive treatment with the selective glycine uptake inhibitor Org25935 in persistent negative symptoms of schizophrenia: Results from the GIANT trial. 49th Annu Meet Am Coll Neuropsychopharmacol (ACNP) 2011, p.258.
80. Ouellet, D., Sutherland, S., Wang, T., Griffini, P., Murthy, V. First-time-inhuman study with GSK1018921, a selective GlyT1 inhibitor: Relationship between exposure and dizziness. Clin Pharmacol Ther 2011, 90(4): 597-604.
81. Roberts, B.M., Shaffer, C.L., Seymour, P.A., Schmidt, C J., Williams, G.V., Castner, S.A. Glycine transporter inhibition reverses ketamine-induced working memory deficits. Neuroreport 2010, 21(5): 390-4.
82. A study of adjunctive treatment of cognitive deficits in schizophrenia (NCT00567203). ClinicalTrials.gov Web site, May 28, 2013.
83. 20101299: Study to evaluate the effect of AMG 747 on schizophrenia negative symptoms (NCT01568216). ClinicalTrials.gov Web site, May 28, 2013.
84. Nations, K.R., Smith, J.A., Tolin, D.F. et al. Evaluation of the glycine transporter inhibitor org 25935 as augmentation to cognitive-behavioral therapy for panic disorder: A multicenter, randomized, double-blind, placebocontrolled trial. J Clin Psychiatry 2012, 73(5): 647-53.
85. Ressler, K.J., Rothbaum, B.O., Tannenbaum, L. et al. Cognitive enhancers as adjuncts to psychotherapy: Use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry 2004, 61(11): 1136-44.
86. Davis, M., Ressler, K., Rothbaum, B.O., Richardson, R. Effects of Dcycloserine on extinction:translation from preclinical to clinical work. Biol Psychiatry 2006, 60(4): 369-75.
87. Szabo, L. Differential effect of GlyT1 inhibitors on the development of ischemic cerebral infarction. J Cereb Blood Flow Metab 2005, 25(Suppl. 1): S15.
88. Harsing, L.G. Jr., Gigler, G., Moricz, K. et al. Antiischemic effects of Org-24461 and NFPS, two glycine transporter type-1 inhibitors. 35th Annu Meet Soc Neurosci (Nov 12-16, Washington, D.C.) 2005, Abst 669.16.
89. Kallo, I., Jekkel, C., Hrabovszky, E. et al. Immunohistochemical and in situ hybridization studies on glycine transporter 1 after transient ischemia in the rat forebrain. Neurochem Int 2008, 52(4-5): 799-808.
90. Hardingham, G.E., Fukunaga, Y., Bading, H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat Neurosci 2002, 5(5): 405-14.
91. Hermanns, H., Muth-Selbach, U., Williams, R. et al. Differential effects of spinally applied glycine transporter inhibitors on nociception in a rat model of neuropathic pain. Neurosci Lett 2008, 445(3): 214-9.
92. Morita, K., Motoyama, N., Kitayama, T., Morioka, N., Kifune, K., Dohi, T. Spinal antiallodynia action of glycine transporter inhibitors in neuropathic pain models in mice. J Pharmacol Exp Ther 2008, 326(2): 633-45.
93. Tanabe, M., Takasu, K., Yamaguchi, S., Kodama, D., Ono, H. Glycine transporter inhibitors as a potential therapeutic strategy for chronic pain with memory impairment. Anesthesiology 2008, 108(5): 929-37.
94. Molander, A., Lido, H.H., Lof, E., Ericson, M., Soderpalm, B. The glycine reuptake inhibitor Org 2535 decreases ethanol intake and preference in male Wistar rats. Alcohol Alcohol 2007, 42(1): 11-8.
95. Lido, H.H., Stomberg, R., Fagerberg, A., Ericson, M., Soderpalm, B. The glycine reuptake inhibitor Org 25935 interacts with basal and ethanolinduced dopamine release in the rat nucleus accumbens. Alcohol Clin Exp Res 2009, 33(7): 1151-7.
96. Ulsaner, J.M., Drott, J.T., Sharik, S.S. et al. Inhibition of glycine transporter 1 attenuates nicotine-but not food-induced cue-potentiated reinstatement for a response previously paired with sucrose. Behav Brain Res 2010, 207(1): 37-43.
97. Cervo, L., Di Clemente, A., Orru, A. et al. Inhibition of glycine transporter-1 reduces cue-induced nicotine seeking, but does not promote extinction of conditioned nicotine cue responding in the rat. Addict Biol 2013, Epub ahead of print.
98. Dhonnchadra, B.A.N., Pinard, E., Alberati, D., Wettstein, J.G., Spealman, R.D., Kantak, K.M. Inhibiting glycine transporter-1 facilitates cocaine-cue extinction and attenuates reacquisition of cocaine-seeking behavior. Drug Alcohol Depend 2012, 122(1-2): 119-26.
99. Lowe, J.A. III, Drozda, S., Fisher, K. et al. [3H]-R-NPTS, a radioligand for the type 1 glycine transporter. Bioorg Med Chem Lett 2003, 13(7): 1291-2.
100. Smith, G., Ruhland, T., Mikkelsen, G. et al. The synthesis and SAR of 2-arylsulfanyl-phenyl piperazinylacetic acids as gly-T-1 inhibitors. Bioorg Med Chem Lett 2004, 14(15): 4027-30.
101. Alberati, D., Hainzl, D., Jolidon, S. et al. Discovery of 4-substituted-8-(2-hydroxy-2-phenyl-cyclohexyl)-2.8-diaza-spiro[4.5]decan-1-one as a Novel class of highly selective GlyT1 inhibitors with improved metabolic stability. Bioorg Med Chem Lett 2006, 16(16): 4311-5.
102. Alberati, D., Cecarelli, S.M., Jolidon, S. et al. Design and synthesis of 4-substituted-8-(2-phenyl-cyclohexyl)-2.8-diaza-spiro[4.5]decan-1-one as a Novel class of GlyT1 inhibitors: Achieving selectivity against the μ opioid and nociceptin/orphanin FQ peptide (NOP) receptors. Bioorg Med Chem Lett 2006, 16(16): 4305-10.
103. Alberati, D., Hainzl, D., Jolidon, S., Kurt, A., Pinard, E., Thomas, A.W., Zimmerli, D. 4-Substituted-8-(1-phenyl-cyclohexyl)-2.8-diaza-spiro[4.5] decan-1-one as a Novel class of highly selective GlyT1 inhibitors with superior pharmacological and pharmacokinetic parameters. Bioorg Med Chem Lett 2006, 16(16): 4321-5.
104. Zheng, Z., O'Brien, J.A., Lemaire, W. et al. A Novel radioligand for glycine transporter1: Characterization and use in autoradiographic and in vivo brain occupancy studies. Nucl Med Biol 2008, 35(3): 315-25.
105. Smith, G., Mikkelsen, G., Eskildsen, J., Bundgaard, C. The synthesis and SAR of 2-arylsulfanylphenyl-1-oxyalkylamino acids as GlyT-1 inhibitors. Bioorg Med Chem Lett 2006, 16(15): 3981-4.
106. Thomson, C.G., Duncan, K., Fletcher, S.R. et al. Sarcosine-based indandione hGlyT1 inhibitors. Bioorg Med Chem Lett 2006, 16(5): 1388-91.
107. Zhao, Z., O'Brien, J.A., Lemaire, W. et al. Synthesis and SAR of GlyT1 inhibitors derived from a series of N-((4-(morpholine-4-carbonyl)-1-(propyl -sulfonyl)piperidin-4-yl)methyl)benzamides. Bioorg Med Chem Lett 2006, 16(23): 5968-72.
108. Rahman, S.S., Coulton, S., Herdon, H.J., Joiner, G.F., Jin, J., Porter, R.A. 1,3-Diaminopropan-2-ol-sulfonamides as potent and selective inhibitors of the glycine transporter type 1. Bioorg Med Chem Lett 2007, 17(6): 1741-5.
109. Walter, M.W., Hoffmann, B.J., Gordon, K. et al. Discovery and SAR studies of Novel GlyT1 inhibitors. Bioorg Med Chem Lett 2007, 17(18): 5233-8.
110. Pinard, E., Alberati, D., Borroni, E. et al. Discovery of benzoylpiperazines as a Novel class of potent and selective GlyT1 inhibitors. Bioorg Med Chem Lett 2008, 18(18): 5134-9.
111. Lowe, J.A. III, Hou, X., Schmidt, C.J. et al. The discovery of a structurally Novel class of inhibitors of the type 1 glycine transporter. Bioorg Med Chem Lett 2009, 19(11): 2974-6.
112. Lowe, J.A. III, DeNinno, S.L., Drozda, S.E. et al. An octahydrocyclopenta[ c]pyrrole series of inhibitors of the type1 glycine transporter. Bioorg Med Chem Lett 2010, 20(3): 907-11.
113. Pinard, E., Alanine, A., Alberati, D. et al. Selective GlyT1 inhibitors: Discovery of [4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5- methanesulfonyl-2((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising Novel medicine to treat schizophrenia. J Med Chem 2010, 53(12): 4603-14.
114. Sugane, T., Tobe, T., Hamaguchi, W. et al. Synthesis and biological evaluation of 3-biphenyl-4-yl-4 phenyl-4H-1,2,4-triazoles as a Novel series of glycine transporter 1 inhibitors. J Med Chem 2011, 54(1): 387-91.
115. Blunt, R., Rorter, R., Johns, A. et al. Acylglycinamides as inhibitors of glycine transporter type 1. Bioorg Med Chem Lett 2011, 21(20): 6176-9.
116. Sugane, T., Tobe, T., Hamaguchi, W. et al. Synthesis and biological evaluation of (4H-1,2,4-triazol-4-yl)isoquinoline derivatives as selective glycine transporter 1 inhibitors. Bioorg Med Chem 2012, 20(1): 34-41.
117. Cioffi, C.L., Wolf, M.A., Guzzo, P.R. et al. Design, synthesis, and SAR of N-((1-(4-(propylsulfonyl)piperazin-1-yl)cycloalkyl)methyl)benzamide inhibitors of glycine transporter-1. Bioorg Med Chem Lett 2013, 23(5): 1257-61.
118. Morrow, J.A., Gilfillan, R., Calpine, C.M., Neale, S.A., Porter, A., Smith, L.H., Thomson, F. Functional characterization of structurally distinct classes of glycine transporter type1 (GlyT1) inhibitors. Soc Neurosci 2011 (Nov 12-16, Washington, D.C.) Abst 236.04.